[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI3008039T1 - Kristalinična oblika MDM2 inhibitorja - Google Patents

Kristalinična oblika MDM2 inhibitorja

Info

Publication number
SI3008039T1
SI3008039T1 SI201431735T SI201431735T SI3008039T1 SI 3008039 T1 SI3008039 T1 SI 3008039T1 SI 201431735 T SI201431735 T SI 201431735T SI 201431735 T SI201431735 T SI 201431735T SI 3008039 T1 SI3008039 T1 SI 3008039T1
Authority
SI
Slovenia
Prior art keywords
crystalline form
mdm2 inhibitor
mdm2
inhibitor
crystalline
Prior art date
Application number
SI201431735T
Other languages
English (en)
Inventor
Matthew Bio
Sebastien Caille
Brian Cochran
Yuanqing Fang
Brian M. Fox
Brian S. Lucas
Lawrence R. Mcgee
Filisaty Vounatsos
Sean Wiedemann
Sarah Wortman
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3008039(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of SI3008039T1 publication Critical patent/SI3008039T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Epoxy Compounds (AREA)
SI201431735T 2013-06-10 2014-06-09 Kristalinična oblika MDM2 inhibitorja SI3008039T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361833196P 2013-06-10 2013-06-10
EP14735785.9A EP3008039B1 (en) 2013-06-10 2014-06-09 Crystalline form of a mdm2 inhibitor
PCT/US2014/041594 WO2014200937A1 (en) 2013-06-10 2014-06-09 Processes of making and crystalline forms of a mdm2 inhibitor

Publications (1)

Publication Number Publication Date
SI3008039T1 true SI3008039T1 (sl) 2021-03-31

Family

ID=51063849

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431735T SI3008039T1 (sl) 2013-06-10 2014-06-09 Kristalinična oblika MDM2 inhibitorja

Country Status (37)

Country Link
US (10) US9376386B2 (sl)
EP (2) EP3805232A1 (sl)
JP (4) JP6998655B2 (sl)
KR (3) KR20160018576A (sl)
CN (3) CN105358530A (sl)
AP (1) AP2015008891A0 (sl)
AR (2) AR096582A1 (sl)
AU (5) AU2014278428B2 (sl)
BR (2) BR112015031004B1 (sl)
CA (4) CA3200532A1 (sl)
CL (3) CL2015003589A1 (sl)
CR (2) CR20210290A (sl)
CY (1) CY1123661T1 (sl)
DK (1) DK3008039T3 (sl)
EA (3) EA202091612A1 (sl)
ES (1) ES2851023T3 (sl)
HR (1) HRP20202065T1 (sl)
HU (1) HUE053047T2 (sl)
IL (4) IL297860A (sl)
JO (2) JOP20200296A1 (sl)
LT (1) LT3008039T (sl)
MA (3) MA38714A1 (sl)
MX (2) MX2015016856A (sl)
MY (1) MY194848A (sl)
NZ (1) NZ714821A (sl)
PE (2) PE20210153A1 (sl)
PH (1) PH12015502705A1 (sl)
PL (1) PL3008039T3 (sl)
PT (1) PT3008039T (sl)
RS (1) RS61192B1 (sl)
SG (2) SG10201801402XA (sl)
SI (1) SI3008039T1 (sl)
TN (1) TN2015000521A1 (sl)
TW (3) TWI698428B (sl)
UA (1) UA121301C2 (sl)
UY (1) UY35605A (sl)
WO (1) WO2014200937A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
CA2850166C (en) 2011-09-27 2019-12-03 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
EP2970237B1 (en) 2013-03-14 2017-09-27 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) * 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
KR102473485B1 (ko) 2013-11-11 2022-12-01 암젠 인크 암의 치료를 위한, mdm2 억제제 및 하나 이상의 추가적 약제학적 활성 제제를 포함하는 조합 요법
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
BR112020022148A2 (pt) * 2018-04-30 2021-04-13 Kartos Therapeutics, Inc. Métodos de tratamento de câncer
AU2019273850B2 (en) * 2018-05-25 2024-11-14 Kartos Therapeutics, Inc. Methods of treating myeloproliferative neoplasms
WO2020047424A1 (en) * 2018-08-31 2020-03-05 Amgen, Inc. Processes for preparing a mdm2 inhibitor
CN110963958A (zh) 2018-09-30 2020-04-07 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
US20230272001A1 (en) * 2020-05-22 2023-08-31 Merck Sharp & Dohme Llc Novel processes for preparing conjugates of the il-2 protein
WO2022043930A2 (en) 2020-08-27 2022-03-03 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
US12054449B2 (en) 2021-08-05 2024-08-06 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate crystalline form and method for manufacturing the same
EP4382509A1 (en) * 2021-08-05 2024-06-12 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate crystalline form and method for preparing same
WO2023039161A1 (en) * 2021-09-09 2023-03-16 Kartos Therapeutics Methods of treating cancer dependent on myc gene expresssion
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483213A (en) * 1947-06-14 1949-09-27 American Cyanamid Co Alpha naphthalene sulfonic anhydride
CH436295A (de) 1961-11-13 1967-05-31 Mcneilab Inc Verfahren zur Herstellung neuer 3-Morpholinone
US3518236A (en) * 1967-07-20 1970-06-30 Uniroyal Inc Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives
DE3246148A1 (de) 1982-12-14 1984-06-14 Troponwerke GmbH & Co KG, 5000 Köln Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2604472B2 (ja) 1989-07-12 1997-04-30 株式会社クラレ 重合性組成物
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
WO1995023135A1 (en) 1991-03-07 1995-08-31 Fisons Corporation Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity
CA2195677C (en) 1994-08-19 2005-11-08 Martin Winn Endothelin antagonists
CA2245587C (en) 1996-02-13 2008-12-30 Abbott Laboratories Novel benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
US6159990A (en) 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
BR9815296A (pt) 1997-08-04 2001-11-20 Abbott Lab Derivados de ácido carboxìlico 3-pirrolidina e ouso dos mesmos como antagonistas endotelina
WO1999031507A1 (en) 1997-12-18 1999-06-24 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries
US6770658B2 (en) 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7195670B2 (en) * 2000-06-27 2007-03-27 California Institute Of Technology High throughput screening of crystallization of materials
US7052545B2 (en) * 2001-04-06 2006-05-30 California Institute Of Technology High throughput screening of crystallization of materials
DE19951418A1 (de) * 1999-10-26 2001-05-03 Merck Patent Gmbh Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
WO2002017912A1 (en) 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
WO2002042731A2 (en) * 2000-11-20 2002-05-30 Parallel Synthesis Technologies, Inc. Methods and devices for high throughput crystallization
EP1358178A2 (en) 2001-01-30 2003-11-05 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
WO2002089738A2 (en) 2001-05-08 2002-11-14 Yale University Proteomimetic compounds and methods
WO2002094787A1 (en) 2001-05-23 2002-11-28 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
WO2003051359A1 (en) 2001-12-18 2003-06-26 F.Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
US6860940B2 (en) * 2002-02-11 2005-03-01 The Regents Of The University Of California Automated macromolecular crystallization screening
US6916833B2 (en) * 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
JP4814228B2 (ja) 2004-05-18 2011-11-16 エフ．ホフマン−ラ ロシュ アーゲー 新規ｃｉｓ−イミダゾリン
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
JP2007297283A (ja) * 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
US7354944B2 (en) 2004-10-18 2008-04-08 Amgen Inc. Thiadiazole compounds and methods of use
MX2007010054A (es) 2005-02-18 2007-09-21 Mitsubishi Pharma Corp Sal de un derivado de prolina, solvato de la misma y metodo de produccion de la misma.
BRPI0607445A2 (pt) 2005-03-16 2009-09-01 Hoffmann La Roche cis-2,4,5-triaril-imidazolinas e seu uso como medicamentos anti-cáncer
WO2006107859A2 (en) 2005-04-04 2006-10-12 Eisai Co., Ltd. Dihydropyridine compounds for neurodegenerative diseases and dementia
AU2006256369B2 (en) * 2005-06-07 2012-08-02 Bar-Ilan University Novel salts of conjugated psychotropic drugs and processes of preparing same
WO2007015929A2 (en) * 2005-07-27 2007-02-08 University Of Toledo Epothilone analogues
RU2442779C2 (ru) 2005-12-01 2012-02-20 Ф. Хоффманн-Ля Рош Аг Производные 2,4,5-трифенилимидазолина как ингибиторы взаимодействия между белками p53 и mdm2, предназначенные для применения в качестве противораковых средств
KR20080091369A (ko) 2006-01-18 2008-10-10 암젠 인크 단백질 키나제 ｂ （ｐｋｂ） 억제제로서 티아졸 화합물
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
CN101595107A (zh) 2006-06-30 2009-12-02 先灵公司 能提高p53活性的有取代哌啶及其用途
WO2008010953A2 (en) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: inhibitors of hiv replication in combination therapy
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
WO2008021339A2 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as pr modulators
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
AU2008231304B2 (en) 2007-03-23 2011-05-12 Amgen Inc. Heterocyclic compounds and their uses
EP2139882B1 (en) 2007-03-23 2013-12-25 Amgen Inc. 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
WO2008118454A2 (en) 2007-03-23 2008-10-02 Amgen Inc. Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (en) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
ES2385692T3 (es) 2007-07-09 2012-07-30 Astrazeneca Ab Derivados de morfolino pirimidina usados en enfermedades relacionadas con mTOR quinasa y/o PI3K
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
WO2009011871A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
BRPI0817850A2 (pt) 2007-10-09 2015-04-07 Hoffmann La Rouche Ag F Cis-imidazolinas quirais
JP5520831B2 (ja) 2007-12-19 2014-06-11 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US20100256191A1 (en) 2007-12-26 2010-10-07 Eisai R&D Management Co., Ltd. Ampa receptor antagonists and zonisamide for epilepsy
AU2009225984A1 (en) 2008-03-21 2009-09-24 Chlorion Pharma, Inc. Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
WO2010030704A2 (en) * 2008-09-10 2010-03-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
CN102159207B (zh) 2008-09-18 2015-02-04 霍夫曼-拉罗奇有限公司 取代的吡咯烷-2-甲酰胺类
EP2387570A1 (en) 2009-01-15 2011-11-23 Amgen, Inc Fluoroisoquinoline substituted thiazole compounds and methods of use
US20120165334A1 (en) 2009-02-18 2012-06-28 Amgen Inc. Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors
MX2011009796A (es) 2009-03-20 2011-12-14 Amgen Inc Inhibidores de la cinasa pi3.
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
CA2760778A1 (en) 2009-05-13 2010-11-18 Amgen Inc. Heteroaryl compounds as pikk inhibitors
WO2010151735A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
AU2010265974B2 (en) 2009-06-25 2014-09-11 Amgen Inc. Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
CA2765819A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses as inhibitors of pi3 k activity
AU2010265932B2 (en) 2009-06-25 2014-11-20 Amgen Inc. Heterocyclic compounds and their uses
CN102574785A (zh) 2009-08-26 2012-07-11 诺瓦提斯公司 四取代的杂芳基化合物和它们作为mdm2和/或mdm4调节剂的用途
MX2012004036A (es) * 2009-10-09 2012-06-27 Achaogen Inc Analogos de aminoglicosidos antibacterianos.
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JP2013519980A (ja) * 2010-02-10 2013-05-30 モチイ，インコーポレイテッド（ディービーエー ヴォクサ） 収差補正暗視野電子顕微鏡
IT1399923B1 (it) * 2010-05-11 2013-05-09 Cbb Net S A Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
EP2663309B1 (en) * 2011-01-10 2017-03-15 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN102153557B (zh) 2011-01-21 2013-03-20 中国科学院上海有机化学研究所 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途
JP6025713B2 (ja) * 2011-04-28 2016-11-16 大塚化学株式会社 アゾジカルボンアミドの新規製造法
TW201309651A (zh) * 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
CA2850166C (en) 2011-09-27 2019-12-03 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
CN103373951B (zh) * 2012-04-28 2016-03-09 上海医药工业研究院 一种拉帕替尼中间体的制备方法
MX362896B (es) 2013-02-19 2019-02-22 Amgen Inc Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
CA2902856C (en) 2013-02-28 2021-02-16 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
EP2970237B1 (en) 2013-03-14 2017-09-27 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط

Also Published As

Publication number Publication date
CN105358530A (zh) 2016-02-24
PE20210153A1 (es) 2021-01-26
HUE053047T2 (hu) 2021-06-28
JP2020147573A (ja) 2020-09-17
TW201922705A (zh) 2019-06-16
EA202091612A1 (ru) 2020-10-05
US20200281912A1 (en) 2020-09-10
AU2024216533A1 (en) 2024-09-19
US20180092898A1 (en) 2018-04-05
IL281807B2 (en) 2023-04-01
AU2020267169B2 (en) 2022-08-25
WO2014200937A1 (en) 2014-12-18
PL3008039T3 (pl) 2021-04-19
ES2851023T3 (es) 2021-09-02
JOP20200296A1 (ar) 2017-06-16
BR122020003153B1 (pt) 2022-09-27
IL297860A (en) 2023-01-01
EP3805232A1 (en) 2021-04-14
BR112015031004B1 (pt) 2022-09-20
MA43288B1 (fr) 2020-10-28
CY1123661T1 (el) 2022-03-24
JP6891322B2 (ja) 2021-06-18
KR20210121270A (ko) 2021-10-07
JP2023089126A (ja) 2023-06-27
US20140364455A1 (en) 2014-12-11
US20160289243A1 (en) 2016-10-06
LT3008039T (lt) 2021-01-25
AU2020267169A1 (en) 2020-12-03
PH12015502705B1 (en) 2016-03-14
EP3008039A1 (en) 2016-04-20
TWI698428B (zh) 2020-07-11
TWI791153B (zh) 2023-02-01
US20160289190A1 (en) 2016-10-06
SG10201801402XA (en) 2018-04-27
CL2019000056A1 (es) 2019-05-03
AP2015008891A0 (en) 2015-11-30
JP6998655B2 (ja) 2022-02-04
AR119727A2 (es) 2022-01-05
NZ714821A (en) 2020-10-30
CN110627708A (zh) 2019-12-31
IL266504A (en) 2019-07-31
AU2014278428A1 (en) 2015-11-26
CL2015003589A1 (es) 2016-06-17
AU2014278428B2 (en) 2018-11-15
JP7263439B2 (ja) 2023-04-24
KR20230019216A (ko) 2023-02-07
PH12015502705A1 (en) 2016-03-14
AU2018260844A1 (en) 2018-11-22
SG11201509896VA (en) 2016-01-28
DK3008039T3 (da) 2021-01-04
MA53572A1 (fr) 2021-10-29
CA3201958A1 (en) 2014-12-18
IL242622B (en) 2019-06-30
AU2022271425B2 (en) 2024-06-13
NZ753956A (en) 2020-12-18
JO3768B1 (ar) 2021-01-31
US20160287570A1 (en) 2016-10-06
TW202035370A (zh) 2020-10-01
MX2015016856A (es) 2016-04-07
RS61192B1 (sr) 2021-01-29
TW201536743A (zh) 2015-10-01
CA3200532A1 (en) 2014-12-18
HRP20202065T1 (hr) 2021-02-19
KR20160018576A (ko) 2016-02-17
MA38714A1 (fr) 2017-10-31
CA3115609C (en) 2023-08-08
CA2914723A1 (en) 2014-12-18
JP2021130685A (ja) 2021-09-09
MY194848A (en) 2022-12-19
CR20210290A (es) 2021-07-23
US20160264526A1 (en) 2016-09-15
EA031254B1 (ru) 2018-12-28
BR112015031004A2 (pt) 2020-05-12
TWI649306B (zh) 2019-02-01
AR096582A1 (es) 2016-01-20
AU2022271425A1 (en) 2022-12-22
PT3008039T (pt) 2021-01-13
TN2015000521A1 (en) 2017-04-06
US20230301974A1 (en) 2023-09-28
CN110003092A (zh) 2019-07-12
US9801867B2 (en) 2017-10-31
IL266504B (en) 2021-04-29
CA2914723C (en) 2021-06-15
CR20160010A (es) 2016-02-04
US9757367B2 (en) 2017-09-12
PE20160113A1 (es) 2016-03-03
CL2021000566A1 (es) 2021-09-03
MX2019012007A (es) 2019-11-11
CA3115609A1 (en) 2014-12-18
IL242622A0 (en) 2016-02-01
US9623018B2 (en) 2017-04-18
US9376386B2 (en) 2016-06-28
US20160289178A1 (en) 2016-10-06
JP2016528179A (ja) 2016-09-15
UA121301C2 (uk) 2020-05-12
US20220280496A1 (en) 2022-09-08
IL281807A (en) 2021-05-31
UY35605A (es) 2015-01-30
EA201592305A1 (ru) 2016-05-31
EA201891642A1 (ru) 2019-08-30
IL281807B (en) 2022-12-01
US9855259B2 (en) 2018-01-02
AU2018260844B2 (en) 2020-08-13
EP3008039B1 (en) 2020-11-11
MA43288A1 (fr) 2020-04-30

Similar Documents

Publication Publication Date Title
IL281807A (en) Processes for the production of crystalline forms of an MDM2 inhibitor
IL279682A (en) Benzoquinolone compounds as VMAT2 inhibitors
IL245865B (en) Form i of crystalline ibrutinib
HK1212333A1 (en) Crystalline forms of a factor xia inhibitor xia
ZA201702252B (en) A selective inhibitor of prosphatidylinositol 3-kinase-gamma
SI3293176T1 (sl) Kristalna oblika inhibitorja PDE4
GB201317609D0 (en) Inhibitor compounds
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
HK1221645A1 (zh) 的苯並喹啉抑制劑
HK1220187A1 (zh) 抗焦慮化合物的晶型
HK1220458A1 (zh) 化合物之多晶型物及鹽
SG11201508998PA (en) Methods of forming a substrate opening
EP2900240A4 (en) CRYSTALLINE FORM OF REVERSE TRANSCRIPTASE INHIBITOR
IL245386A0 (en) A crystalline beta-lactamase inhibitor
EP2959896A4 (en) INHIBITOR OF PHOSPHORYLATION OF PROTEIN T
GB201300903D0 (en) Crystalline Form
GB201321328D0 (en) Inhibitor compounds